Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Dyne Therapeutics (DYN), a clinical-stage company developing therapeutics for genetically driven neuromuscular diseases, has granted inducement equity awards to three new employees. The awards include:

• Non-statutory stock options to purchase 330,200 shares at the closing price on April 14, 2025
• 101,900 restricted stock units

The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year, followed by quarterly installments. The restricted stock units vest annually over four years in equal installments. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and are subject to Dyne's 2024 Inducement Stock Incentive Plan.

WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to three new employees. The awards were approved by Dyne’s Compensation Committee and made as an inducement material to the new employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 330,200 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on April 14, 2025, and restricted stock units with respect to an aggregate of 101,900 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938

FAQ

What equity awards did Dyne Therapeutics (DYN) grant to new employees in April 2025?

DYN granted 330,200 non-statutory stock options and 101,900 restricted stock units to three new employees.

How do the stock options vest in Dyne Therapeutics' April 2025 inducement grants?

The stock options vest over 4 years, with 25% vesting after year one and the remainder in 12 quarterly installments.

What is the vesting schedule for DYN's restricted stock units granted in April 2025?

The restricted stock units vest over 4 years in four equal annual installments.

Under which regulatory framework were DYN's April 2025 inducement grants approved?

The grants were approved under Nasdaq Listing Rule 5635(c)(4) and Dyne's 2024 Inducement Stock Incentive Plan.